slides · global inventory
Expose Contradiction
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 14,162
Current window 10,321-10,350
Pages 473
Rows per page 30
Slide function
10,321-10,350 of 14,162
319
The slide uses a Q&A transcript format to expose flaws in clinical trial integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
320
The slide uses a Q&A format to present expert testimony from a trial investigator.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
321
The slide uses a Q&A transcript format to expose flaws in the clinical trial design regarding pill size.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
322
The slide uses a Q&A transcript format to undermine the company's product value proposition.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
323
The slide uses a combination of summary text and direct interview transcripts to highlight expert skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
324
The slide uses a Q&A format to highlight the failure of the trial's blinding protocol.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
325
The slide uses direct quotes from a pediatric endocrinologist to build a case against the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
326
The slide uses Q&A transcripts to expose the risks of the drug and the burden of monitoring.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
327
The slide uses a bolded summary paragraph at the top, followed by a detailed Q&A transcript with yellow highlighting on key quotes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
331
The slide uses direct quotes from an endocrinologist/KOL to undermine the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
332
The slide uses a direct quote from an endocrinologist to undermine the primary endpoint of a clinical trial.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
333
The slide uses direct quotes from a trial investigator to undermine the company's value proposition.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
334
The slide uses direct quotes from a trial investigator to undermine the value proposition of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
335
The slide uses direct quotes from an interview to highlight the discrepancy between public promotion and private clinical reality.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
336
The slide uses a Q&A format to highlight the investigator's reluctance and admission of clinical risks.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
337
Uses direct quotes from an investigator to undermine the credibility of clinical trial data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
338
The slide uses a Q&A transcript format to highlight potential misclassification of adverse events in a clinical trial.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
340
The slide presents a transcript of an expert consultation call to undermine the market potential of Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
341
The slide uses direct quotes from an expert consultation to undermine the product's value proposition.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
342
The slide uses a Q&A format to highlight the expert's negative sentiment toward the drug's efficacy and the company's investor materials.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
343
The slide presents a direct challenge to the commercial viability of 'Vykat' by highlighting a physician's preference for a cheaper, off-label alternative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
345
The slide uses expert quotes to undermine the company's claims regarding the drug's safety profile and market potential.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
346
The slide uses highlighted text to emphasize critical quotes from medical experts.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
347
The slide uses a combination of summary text and verbatim Q&A transcripts to highlight negative sentiment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
349
The slide uses direct quotes to undermine the market potential and safety profile of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
350
The slide presents a Q&A format highlighting expert skepticism regarding the drug's safety profile and market relevance.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
351
The slide uses direct quotes to highlight physician skepticism and lack of awareness regarding the drug's trial flaws.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
352
The slide uses direct quotes to highlight the expert's negative sentiment toward the drug and the clinical trial methodology.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
354
The slide uses a Q&A format to highlight expert skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
355
The slide uses a Q&A format to build a case for market substitution risk.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit